Welcome to our dedicated page for ONCOLOGIX TECH news (Ticker: OCLG), a resource for investors and traders seeking the latest updates and insights on ONCOLOGIX TECH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONCOLOGIX TECH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONCOLOGIX TECH's position in the market.
On May 2, 2022, Oncologix Tech, Inc. (OTC: OCLG) announced a definitive business combination agreement with DNAGO.Ai, a company specializing in clinical genetic testing. Post-combination, OCLG will be renamed DNAGO and continue operations focused on genetic testing for over 7,000 rare diseases. The transaction is expected to finalize in Q2 2022, pending shareholder approval. CEO Frank I Igwealor resigned, with Madeline Choi appointed as the new CEO. The firm emphasizes its mission to make affordable genetic testing accessible through advanced AI technology.
FAQ
What is the market cap of ONCOLOGIX TECH (OCLG)?
